's Information

Seung-Jung Park, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. The PREVENT Trial: Confirmative RCT of Preventive PCI of Vulnerable Plaque
  2. Case 1. Practical Issue of Left Main & Multi-Vessel PCI: Make it Simple!
  3. Revascularization for Left Main Disease: Updated Data, Global Guidelines and Beyond
  4. LM PCI: Make-It-Simple!
  5. What Really Matters in LM Bifurcation PCI: Concept or Technique?
  6. 10 Year's Journey of AMC TAVR
  7. PREVENT Trial
  8. Functionally Insignificant Vulnerable Plaque; Treat or Not?
  9. Non-LM Bifurcation PCI in 2023: Don't Touch Small Side Branch, Evolving Changes in AMC Practice
  10. Insight from All Data for Triple Vessel Disease
  11. Don't Touch Small Side Branch! Concept Changes After ISCHEMIA Study
  12. My Approach to Multi-vessel Disease - Master\'s Skill Secret
  13. Non-LM Bifurcation Revascularization 2022: Guidelines and Concept Change
  14. The Last 10 Year TAVR Path and Achievement of ASAN MEDICAL CENTER
  15. Updated Techniques and Concepts 2021 for Complex Left Main PCI
  16. Why Mismatching? FFR vs. Angiographic %DS
  17. Minimalist TAVR: AMC Experience
  18. What Is the Practical Approach to LM/MVD Revascularization? - Make It Simple!!
  19. PREVENT: Physiology and Imaging for PREVENTing Future Events
  20. [Debate: Should All CTOs Be Opened?] Cons
  21. MAIN COMPARE: 10-Year Follow-up
  22. What Is the Benefit of CTO PCI?: Insights from the DECISION CTO
  23. Physiology-Guidance: Synergetic Hybrid Approach for Complex PCI
  24. 10-year Outcomes of MAIN-COMPARE Study: Main and Key Substudies
  25. [Featured Lecture] LM-PCI: New Techniques, Concept, and Insights from the LM Pioneer
  26. PCI vs CABG for Left Main and Multivessel Disease
  27. Integrated Use of FFR and IVUS in LM PCI
  28. TAVR in Asia, Korea, and AMC
  29. PREVENT Trial: Update and Interesting Cases
  30. The Lesson from DECISION-CTO Trial
  31. All the Data from IRIS-FFR Registry
  32. To Treat or Not to Treat for Gray Zone FFR(0.76-0.80)
  33. [Debate: Should All CTOs Be Opened?] Con
  34. Top 10 Tips on Left Main PCI
  35. Keynote Lecture on Left Main PCI: Expert\'s Concept and Technique
  36. Future Perspective of Bioresorbable Vascular Scaffolds (ABSORBII, ABSORBIII, AIDA-AMC Registry) : Is It a Crisis or a Chance to Move Forward?
  37. Can BRS Stabilize Vulnerable Plaque?: PREVENT
  38. [Debate: Left Main Disease - How to Treat in Contemporary Era?] LM Is No Longer Surgical Disease.
  39. How To Manage Grey Zone FFR?: Data from IRIS FFR Registry
  40. Impact of Complete Revascularization for Multivessel PCI
  41. PREVENT Trial: Update and Insight from Plaque Imaging
  42. Impact of Complete Revascularization for MVD PCI
  43. Why PCI ? - Rationale for PCI / - Patient & Lesion Selection
  44. Is It a Matter of Technique or Concept?: Left Main and Bifurcation PCI
  45. From STABLE to PREVENT
  46. FFR and Clinical Outcomes: Evidence Has Never Been Stronger
  47. Left Main PCI: The Simpler, The Better
  48. Case 1: Left Main Disease
  49. Left Main & Bifurcation PCI: Is It a Matter of Technique or Concept?
  50. Relationship Between FFR and Clinical Outcome: Data from IRIS-FFR Registry
  51. Can We Prevent Events of Vulnerable Plaques?: From STABLE to PREVENT
  52. FFR: How to Change Our Practice?
  53. Integrated Approach for LM PCI Using IVUS and FFR
  54. What Happened in Deferred Lesion: Insight from IRIS-FFR Registry
  55. Please Keep It: IVUS-Guidance for LM Stenting
  56. Left Main Disease Is Not Surgical Treatment Any More: Data-Supported 2015
  57. Fate of Deferred Lesion: Insight from Prospective IRIS-FFR Registry
  58. Plaque Stabilization and Preemptive BVS: From STABLE to PREVENT
  59. How to Treat? - Functionally Insignificant Vulnerable Plaque: STABLE and PREVENT
  60. Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
  61. Can We Prevent Future Event?: PREVENT Trial - Design and Rationale
  62. Impact of FFR
  63. IVUS Is Enough!
  64. How Good FFR Guided in Real Practice from Asan PCI and Multivessel Registry & IRIS-FFR Registry
  65. Can We Prevent DEFER Lesion Event? PREVENT Trial - Design and Rationale
  66. Asian Multicenter Registry
  67. FFR Guided Clinical Practice of Left Main PCI
  68. [FFR Use at CathLab: More & Better] FFR-guided PCI in Routine Practice: Lessons from the AMC Experience
  69. Temporal Trends and Outcomes of Contemporary LM Treatment: From the Asan Left Main Registry
  70. Either FFR or IVUS Is Acceptable, but Choose Your Cutoff Values Wisely!
  71. 15-year Temporal Change of LM Revascularization: Lesson from Asan Main Registry
  72. Do You Want to Treat?: Functionally Insignificant Vulnerable Plaque - No, I Don\'t. We Can\'t Predict Fate of Vulnerable Plaque.
  73. Meta-analysis of LM PCI: PCI Using DES vs. CABG
  74. How Good FFR Guided in Real Practice: Data from Asan PCI and Multivessel Registry
  75. IVUS-MLA and FFR
  76. Coronary Angiography versus FFR: Why Mismatches
  77. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] No, I Don't
  78. TAVI in Korea: How to Avoid Conduction Disturbance..
  79. PCI vs CABG from BARI to SYNTAX: Is the Game over?
  80. Functional Evaluation Is Necessary !
  81. Impact of Functional Angioplasty in Our Real Practice!
  82. Impact of Functional Angioplasty to Current Practice: Trends in Clinical Outcomes of PCI with Drug Eluting Stents
  83. Featured Lecture: The Fate of PCI for Multi-Vessel Disease in the Era of COURAGE, SYNTAX, FAME, and FREEDOM
  84. Now, Do the IVUS-MLA Criteria Need to Be Adjusted ?
  85. When and How We Utilize Imaging and Functional Information in LM Stenting
  86. Clinical Outcomes from RCTs and Registries
  87. Why Visual-functional Mismatch? New Insight from Computational Simulation and Imaging Data
  88. New Frontiers in Left Main Intervention; Functional Angioplasty and New Optimizing Criteria
  89. Why Visual-functional Mismatches?
  90. FFR Guided and IVUS Supported Functional Angioplasty
  91. Device Positioning Is Crucial.
  92. Functional PCI for LM Stenosis: IVUS and FFR Guided
  93. [Debate: Can We Safely Defer PCI Just Based on FFR>0.80?] Yes, Already Proven.
  94. Functional Angioplasty - Insight from FFR and IVUS
  95. Why Visual-Functional Mismatches?
  96. Invited Case Presentation & Focus Review: FFR Guided Spot Stenting for Tandem Lesion PCI
  97. Discrepancy between Anatomic vs. Functional Parameters (IVUS vs. FFR)
  98. It's Not Enough !
  99. Long and Tandem Lesion Intervention: FFR Guided Spot Stenting
  100. Pre-COMBAT: LM Disease Revascularization - PCI vs. CABG Randomization Study
  101. Is Angiography Enough To Guide LMT PCI? - 'Functional Approach Should Be Considered!'
  102. Left Main PCI: Where We Are? Where We Are Going?
  103. Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease
  104. Anatomic vs. Functional Assessment of Coronary Artery Stenosis: Can IVUS-Derived Minimal Lumen Area Predict FFR < 0.8?
  105. Case Based Learning
  106. Paradigm Shift to Functional Angioplasty: FFR Guided Decision Making, IVUS Guided Optimization
  107. PCI in Unprotected Left Main Disease (MAIN-COMPARE, SYNTAX, and Several Registries)
  108. Xience V in Real Life
  109. Duration of Dual Antiplatelet Therapy in DES
  110. Insight into LM PCI from Main-COMPARE, SYNTAX LM, and Registries
  111. Coronary Intervention
  112. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
  113. DECISION CTO_New Horizon in CTO Treatment; Randomized Study Proposal
  114. Comparison of Sirolimus- and Paclitaxel-Eluting Stents vs Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial
  115. Future Clinical Study for Nobori Stent in Korea
  116. The Impact of Diabetes in the DES Long-Term Outcome
  117. Prognostic Influence of DM on Long-Term Clinical Outcomes and Stent Thrombosis Following DES Implantation in Asian: AMC Experience
  118. Can SYNTAX Score Be Feasible to Predict Outcomes of LM Revascularization?: Application to MAIN-COMPARE Registry
  119. Can Carotid Artery Stenting Before CABG Reduce Perioperative Stroke ?
  120. Tailores Approach with DES for Long Coronary Lesions
  121. \"ZEST\" Trial
  122. PCI vs CABG in Left Main Disease: Main Registry Update
  123. Impact of Diabetes on Long-Term Outcomes of Drug-Eluting Stents in Asian Patients
  124. Long-Term Evaluation of DES vs. BMS; 10-Year Experience from Single Center Registry
  125. How Can We Optimize Good Result in the Long Coronary Lesion ?
  126. Left Main Trifurcation Intervention
  127. LM Intervention Is Still an Available Option Despite Late Stent Thrombosis?
  128. VH-IVUS: Matched and Mismatched
  129. Nobori Stent, Update
  130. VH Experience in Real World: Asan Medical Center
  131. How to Treat - Unprotected Left Main Disease
  132. LM Bifurcation Intervention Guideline for COMBAT
  133. Safety and Efficacy of Cypher on Complex Lesion
  134. LM stenting -Cypher
  135. Drug Eluting Stent: Real World Experience(AMC Registry Study)
  136. Long Cypher Multicenter Registry Study
  137. Aggressive Colesterol Lowering Therapy after PCI(Percutaneous Coronary Intervention)
  138. Long-DES: Study presented in TCT 2004
  139. Treatment of In-Stent Restenosis : Drug Eluting Stent versus Brachytherapy
  140. Is bypass surgery needed for elderly patients with left main coronary artery disease? - CON l
  141. Safety and Effectiveness of Sirolimus Eluting Stent for Left Main Coronary Artery Stenosis
  142. Long Cypher?Multicenter Registry Study in Korea
  143. Bail-out stenting for Unprotected Left Main Coronary Artery Dissection during Catheter-Based Procedure
  144. Cypher vs. Taxus ; Taxus vs. Cypher - Is there something different ?
  145. Primary Stenting for Unprotected Left Main Coronary Artery Stenosis during AMI
  146. Percutaneous Mitral Valvuloplasty: State of Art
  147. Coronary Perforation of Proximal LAD after Debulking for LMCA Ostial Stenosis, Treated with PTEE-covered JoStent
  148. Why Polymer Coated Paclitaxel Stents
  149. Percutaneous Intervention of Unprotected left main Disease
  150. Technical Feasibility, Safety, and Clinical Outcome of Stenting of Unprotected Left Main Coronary Artery Bifurcation Narrowing Equipment Overview of DCA Device Percutaneous Intervention of Unprotected Left Main Disease
  151. PCI for Chroic Total Occlusion
  152. Drug-Eluting Stent
  153. Left Main Ostial Stenosis after Aortic Valve Replacement
  154. Percutaneous Intervention of Unprotected Left Main Ostial and Shaft Disease
Conference Slides
Category